Oseni Tablet, Film Coated
Product Images NDC 64764-253

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Oseni (NDC 64764-253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oseni 01)

Chemical structure diagram of the active ingredients alogliptin and pioglitazone, showing their molecular structure and arrangement as presented in the product label for OSENI.*

FDA Label Image

Chemical Structure (Oseni 02)

Chemical structure diagram of alogliptin and pioglitazone hydrochloride, the active ingredients in OSENI tablets. The diagram depicts the molecular connectivity including rings, bonds, and functional groups relevant to the compound.*

FDA Label Image

Figure 1 (Oseni 03)

A forest plot chart illustrating the pharmacokinetic interactions of alogliptin when coadministered with various drugs. The chart shows the ratio and 90% confidence intervals (CI) for the area under the curve (AUC) and maximum concentration (Cmax) compared to alogliptin alone. Each drug and its dosage regimen are listed with no dose adjustment recommended for any combination.*

FDA Label Image

Figure 2 (Oseni 04)

A forest plot displaying pharmacokinetic interactions of alogliptin with various coadministered drugs. The graph shows ratios and 90% confidence intervals for area under curve (AUC) and maximum concentration (Cmax) for alogliptin alone and in combination, with recommendations indicating no dose adjustments are needed. The chart categorizes drugs by their renal excretion or inhibition/induction of CYP enzymes or transport proteins.*

FDA Label Image

Figure 3 (Oseni 05)

A bar chart presenting least squares mean change in A1C (%) for various treatments including placebo, alogliptin (25 mg), pioglitazone (15 mg, 30 mg, 45 mg), and combinations of alogliptin with pioglitazone at different doses. The chart compares efficacy in lowering A1C from baseline mean levels, with significant reductions marked for combination treatments versus individual components.*

FDA Label Image

Figure 4 (Oseni 06)

A Kaplan-Meier cumulative event probability curve comparing alogliptin (A) and placebo (P) over a 30-month period from randomization. The x-axis represents months from randomization, and the y-axis shows cumulative event probability. The graph includes numbers at risk for both groups at various time points and a hazard ratio with 95% confidence interval comparing alogliptin to placebo.*

FDA Label Image

12-5-15bottlelabel (Oseni 07)

OSENI 12.5 mg/15 mg tablets packaging label for oral film-coated tablets containing alogliptin and pioglitazone. The label specifies prescription use, a count of 30 tablets, and that it is distributed by Takeda Pharmaceuticals America, Inc. Dosage details and storage instructions are visible, along with an NDC code and barcode.*

FDA Label Image

12-5-30bottlelabel (Oseni 08)

OSENI 12.5 mg/30 mg film-coated oral tablets label by Takeda Pharmaceuticals America, Inc. The label includes dosage strength, brand and generic names (alogliptin and pioglitazone), package count of 30 tablets, storage instructions, and a barcode with NDC 64764-123-03.*

FDA Label Image

12-5-45bottlelabel (Oseni 09)

Oseni 12.5 mg/45 mg film-coated tablets label showing alogliptin and pioglitazone as active ingredients. The label indicates 30 tablets per bottle, marketed by Takeda Pharmaceuticals America, Inc. Storage instructions and a warning to dispense with a medication guide are included. The NDC code 64764-124-03 is visible along with a barcode.*

FDA Label Image

25-15bottlelabel (Oseni 10)

Label for OSENI tablets, containing alogliptin and pioglitazone, with a strength of 25 mg/15 mg. The package shows 30 film-coated tablets and includes storage instructions. Distributed by Takeda Pharmaceuticals America, Inc. The label displays the NDC 64764-251-03 and includes the Takeda logo.*

FDA Label Image

25-30bottlelabel (Oseni 11)

Oseni 25 mg/45 mg tablets (alogliptin and pioglitazone) film-coated oral tablets in a 30-tablet package by Takeda Pharmaceuticals America, Inc. The label includes dosage details, storage instructions, and a medication guide notice.*

FDA Label Image

25-45bottlelabel (Oseni 12)

Label for OSENI tablets containing alogliptin and pioglitazone, strength 25 mg/30 mg. The film-coated oral tablets are prescription only and come in a package of 30 tablets. The label includes storage instructions, dosage information, and is distributed by Takeda Pharmaceuticals America, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.